Hong Kong, China

HUTCHMED, a Hong Kong-based biopharmaceutical company, is on track to become a global leader in the discovery, development, and commercialisation of innovative, highly selective oral tyrosine kinase inhibitor therapies for oncology and immunological indications.

Investment Perspective

HUTCHMED’s clearly articulated strategy is delivering, with consistent clinical and commercial execution marking its continuing transition from a development stage company into a profitable commercial organisation. Growth in Oncology/ Immunology revenues, defined investment priorities, and a global partnering strategy should all contribute to achieving a FY25 breakeven target. HUTCHMED aims to expand its marketed portfolio of oncology drugs in China from three to six or seven by FY25, addressing blood disorders as well as solid tumours. First global launch of an in-house product, by partner Takeda, could occur in 2024, subject to a positive FDA approval decision in November. Our updated HUTCHMED valuation is $5.74bn ($32.95 per ADS), £4.78bn and HK$44.75n (549p or HK$51.40 per share).

Market information



Surfing the ‘waves’ towards profitability
Outlook | 07 Sep 2023
Delivering on sharpened goals and priorities
Lighthouse | 01 Aug 2023
ASCO 2023: a growing body of evidence for fruquintinib
Update | 22 Jun 2023

Recent News

Presentation of results from the Phase IIIb trial of savolitinib at WCLC 2023
12 Sep 2023
Completion of enrollment in tazemetostat China bridging study in r/r FL
12 Sep 2023
BTD granted in China for savolitinib in Gastric Cancer
29 Aug 2023
Sovleplenib ITP Phase III met primary endpoint in China
21 Aug 2023